Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

Abstract Background The purpose of this study was to compare clinical outcomes of Erlotinib versus Gefitinib in the treatment of Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and newly diagnosed brain metastases. Methods Consecutive Asian patients with exon 19 EGFR-mutant lung adenocar...

Full description

Bibliographic Details
Main Authors: Ye Jiang, Jing Zhang, Juanjuan Huang, Bo Xu, Ning Li, Lei Cao, Mingdong Zhao
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Pulmonary Medicine
Subjects:
Erlotinib
Gefitinib
Lung adenocarcinoma
Overall survival
Online Access:http://link.springer.com/article/10.1186/s12890-018-0734-1

Internet

http://link.springer.com/article/10.1186/s12890-018-0734-1

Similar Items